News

Ra Pharma Set to Launch Phase 3 Trial Testing Zilucoplan on Patients with Generalized Myasthenia Gravis

Ra Pharmaceuticals is preparing to launch a Phase 3 clinical trial to assess the therapeutic potential of zilucoplan for the treatment of patients with generalized myasthenia gravis (gMG). This comes after the company’s completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA). The 12-week study — a single, pivotal,…

Soliris May Be Best Immunotherapy for MG Patients, Study Suggests

Soliris (eculizumab) may be the most effective and well-tolerated immunotherapy for patients with myasthenia gravis (MG), according to an analysis of multiple studies. The research, “Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta‐analysis,” was published in the journal CNS Neuroscience…